Anat Cohen-Dayag, Compugen CEO

Com­pu­gen touts ovar­i­an can­cer da­ta in com­bo with Op­di­vo, an­ti-TIG­IT from ex-part­ner Bris­tol My­ers

Com­pu­gen pre­sent­ed a batch of da­ta from ear­ly-stage tri­als of its an­ti-PVRIG can­di­date in dual and triple com­bi­na­tion stud­ies, in­clud­ing one with an an­ti-TIG­IT ther­a­py, but the pair­ings are no longer part of the biotech’s strat­e­gy af­ter it re­cent­ly axed a years­long Bris­tol My­ers Squibb col­lab­o­ra­tion.

And, for a brief pe­ri­od this fall, the in­di­ca­tion was not a fo­cus of the biotech’s fu­ture de­vel­op­ment plans, but Tues­day’s da­ta are enough to shore up con­fi­dence for an­oth­er study in plat­inum re­sis­tant ovar­i­an can­cer, the Holon, Is­rael-based drug de­vel­op­er said Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.